Inovio Pharmaceuticals Inc. is a leading developer of therapeutic and preventive vaccines against cancers and infectious diseases. The company’s new DNA vaccine delivery technology was recently highlighted in a paper published in the scientific journal Human Vaccines.

Inovio’s DNA technology provides enabling capabilities of electroporation without contacting the skin. While the company’s current devices have been proven safe and well-tolerated in humans, Inovio is advancing its research to get maximal device characteristics to conduct mass vaccinations.

The Human Vaccines paper entitled “Piezoelectric permeabilization of mammalian dermal tissue for in vivo DNA delivery leads to enhanced protein expression and increased immunogenicity,” written by Inovio scientists, describes the electroporation method and investigates the use of the method in animal testing.

Dr. J. Joseph Kim, Inovio’s president and CEO, said the Inovio continues to hold strong position in vaccine delivery methods and noted the advantages of the new DNA vaccine device.

“Inovio continues to raise the bar in terms of technological innovation that will further optimize electroporation-based delivery of DNA-based therapeutics and vaccines for patients of all ages. While still enabling levels of vaccine potency that we have observed with our existing electroporation devices, this new contactless delivery method is non-invasive and amenable to the design of devices that are low-cost, portable, and extremely easy to use,” Dr. Kim stated in the press release.

For more information visit www.inovio.com